Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab? mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.
-
所属行业
-
生物技术研究
-
规模
-
1,001-5,000 人
-
总部
-
Waltham,Massachusetts
-
类型
-
上市公司
-
创立
-
2009
-
领域
-
Preclinical Services、Animal Models、Gene Targeting、Humanized Immune-oncology Checkpoint Mouse、Immune-deficient mouse model、Antibody Research and Development、Animal Production and Breeding、In vivo study、Fully human antibody mouse、Immuno-Oncology、Antibody discovery、Preclinical CRO、Pharmacology和Antibody Licensing